Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1604360 | PMC |
| http://dx.doi.org/10.1136/bmj.1.6120.1139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secukinumab in refractory non-infectious anterior uveitis.
Front Ophthalmol (Lausanne)
February 2025
Ophthalmology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Background: Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.
View Article and Find Full Text PDFIL23p19 therapies for moderately-to-severely active ulcerative colitis.
Expert Opin Biol Ther
March 2025
Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
Introduction: Ulcerative colitis (UC) is a chronic, relapsing and remitting, inflammatory bowel disease. Monoclonal antibodies targeting interleukin (IL)-23p19 have been developed to treat chronic inflammatory diseases mediated by aberrant IL23/Th17 responses, including psoriasis, psoriatic arthritis, and Crohn's disease. More recently, these agents have been evaluated for the treatment of moderately-to-severely active UC.
View Article and Find Full Text PDF[Emerging therapies for inflammatory rheumatic diseases].
Rev Med Suisse
March 2025
Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Rheumatologists face daily challenges in managing inflammatory rheumatic diseases (rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis). Significant advancements in our therapeutic arsenal have occurred over the past decades. However, achieving remission remains an unattainable goal for many patients, highlighting the need for new treatment options.
View Article and Find Full Text PDFEfficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis.
Dermatol Reports
February 2025
Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.
Psoriasis is an inflammatory chronic disease of the skin, typically located on the extensor surfaces of the body and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these complex patient populations, especially after the failure of one or multiple lines of therapy.
View Article and Find Full Text PDFExploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.
Exploration (Beijing)
February 2025
Immune-mediated inflammatory diseases (IMIDs) impose an immeasurable burden on individuals and society. While the conventional use of immunosuppressants and disease-modifying drugs has provided partial relief and control, their inevitable side effects and limited efficacy cast a shadow over finding a cure. Promising nucleic acid drugs have shown the potential to exert precise effects at the molecular level, with different classes of nucleic acids having regulatory functions through varying mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!